Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03742414 · ClinicalTrials.gov registry record · Phase 2
Seal, Stopping Eczema and Allergy Study
A Phase 2 study of Atopic Dermatitis and Eczema, sponsored by Kari Nadeau, MD, PhD.
- Active
- Registry status
- Phase 2
- Development phase
- 398
- Enrollment target
- 5
- Study locations
NCT03742414: Active Phase 2 study of Atopic Dermatitis and Eczema, sponsored by Kari Nadeau, MD, PhD.
NCT03742414 is a Phase 2 study of Atopic Dermatitis and Eczema that is active but no longer recruiting, run by Kari Nadeau, MD, PhD. The registered enrollment target is 398 participants, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (34% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03742414, a Phase 2 study of Atopic Dermatitis and Eczema, is active but no longer recruiting, sponsored by Kari Nadeau, MD, PhD.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 398 participants
- Enrollment target
- 5
- Study locations
Study Summary
This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactive use of fluticasone propionate cream, against reactive AD therapy, to reduce the occurrence and severity of AD in early infancy and thereby prevent food allergy (FA).
Primary Outcome
Sensitization is defined as food-specific IgE \> 0.1 kU/L
Conditions Studied
Interventions
- OTHER Standard of Care
- COMBINATION_PRODUCT Tri-lipid skin barrier cream (Epiceram)
- COMBINATION_PRODUCT Fluticasone propionate Cream 0.05%
Study Locations (5)
California
- Sean N. Parker Center for Allergy & Asthma Research at Stanford University - Palo Alto
Colorado
- Division of Pediatric Allergy and Clinical Immunology, National Jewish Health - Denver
Illinois
- University of Chicago - Chicago
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
London
- • King's College London and Guy's and St. Thomas' NHS Foundation Trust, UK - London
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 398 participants |
| Start Date | 2021-06-30 |
| Est. Completion | 2028-06-30 |
| Phase | Phase 2 |
What the registry record for NCT03742414 still lists
NCT03742414 is an interventional study that assigns participants to a tested intervention. The registered 398 participants enrollment target is mid-sized for trials with a published cap, below the 607-participant average among 150 other Atopic Dermatitis trials with a reported enrollment target (34% lower).
The record links to 4 conditions, with Atopic Dermatitis appearing as the primary indexed condition, and to 3 interventions - of which Standard of Care is the first listed.
NCT03742414 lists 5 locations in 5 states (California, Colorado, Illinois).
Frequently Asked Questions
What is clinical trial NCT03742414 about?
NCT03742414 is a clinical study titled "Seal, Stopping Eczema and Allergy Study". This is a randomized, controlled trial designed for children who are have already developed atopic dermatitis (AD or eczema) by 12 weeks of age. The aim is to compare the effect of proactive sequential skin care, including the twice-daily use of a tri-lipid skin barrier cream (Epiceram) and proactiv...
What is the current status of trial NCT03742414?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 398 participants. The study started on 2021-06-30. Estimated completion is 2028-06-30.
What conditions does trial NCT03742414 study?
This clinical trial studies the following conditions: Atopic Dermatitis, Eczema, Atopic Dermatitis Eczema, Eczema, Infantile.
What interventions are being tested in trial NCT03742414?
The interventions under investigation include: Standard of Care (OTHER), Tri-lipid skin barrier cream (Epiceram) (COMBINATION_PRODUCT), Fluticasone propionate Cream 0.05% (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT03742414?
This trial is sponsored by Kari Nadeau, MD, PhD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03742414 being conducted?
This trial has 5 study locations across California, Colorado, Illinois, Ohio, London. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atopic Dermatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03742414's enrollment target sits among peer trials
398 35th of 150 higher than 116 of 150 other Atopic Dermatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atopic Dermatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Cardamom and Topical Roseomonas in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess the Efficacy and Safety of Afimkibart (RO7790121) in Participants With Moderate to Severe Atopic Dermatitis
RECRUITING · Phase 2
-
Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
RECRUITING · Phase 2
-
A Study Evaluating TRIV-509 in Atopic Dermatitis
RECRUITING · Phase 2
-
A Study to Assess Molecular Changes in Adult Participants With Moderate to Severe Hidradenitis Suppurativa or With Moderate to Severe Atopic Dermatitis Receiving Subcutaneous Injections of Lutikizumab
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05365581 · 398 participants · Phase 1
A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer
- NCT03165734 · 399 participants · Phase 3
A Phase 3 Study of Pacritinib in Patients With Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis
- NCT05022862 · 399 participants · NA
Economic Incentives and vDOT for Latent Tuberculosis Infection
- NCT00601939 · 397 participants · NA
Effectiveness of Empowerment Group Sessions for Treating Suicidal African American Women in Abusive Relationships
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI